Sources | Names Used |
---|---|
CTRPv2 | SNX-2112:bortezomib (250:1 mol/mol) |
PharmacoGx | SNX-2112:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | DDX46 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
mRNA | REXO1 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
mRNA | CD109 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
mRNA | TBC1D4 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
mRNA | GTF2F2 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
mRNA | CTRB2 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
mRNA | AL022067.1 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
mRNA | CHCHD7 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
mRNA | SPAG9 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
mRNA | TNFRSF1A | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |